Survey of current practices from an international task force for gynecological stereotactic ablative radiotherapy.
Dose Fractionation, Radiation
Female
Genital Neoplasms, Female
/ diagnostic imaging
Humans
Lymphatic Metastasis
Multimodal Imaging
Neoplasm Recurrence, Local
Organs at Risk
/ radiation effects
Practice Patterns, Physicians'
/ statistics & numerical data
Radiation Oncologists
/ statistics & numerical data
Radiosurgery
/ statistics & numerical data
Radiotherapy Planning, Computer-Assisted
Salvage Therapy
Surveys and Questionnaires
Consensus
Gynecological
Radiation
SABR
SBRT
Stereotactic
Journal
Radiation oncology (London, England)
ISSN: 1748-717X
Titre abrégé: Radiat Oncol
Pays: England
ID NLM: 101265111
Informations de publication
Date de publication:
30 Jan 2020
30 Jan 2020
Historique:
received:
30
07
2019
accepted:
15
01
2020
entrez:
1
2
2020
pubmed:
1
2
2020
medline:
21
10
2020
Statut:
epublish
Résumé
Stereotactic Ablative Radiotherapy (SABR) is an effective treatment that improves local control for many tumours. However, the role of SABR in gynecological cancers (GYN) has not been well-established. We hypothesize that there exists considerable variation in GYN-SABR practice and technique. The goal of this study is to describe clinical and technical factors in utilization of GYN-SABR among 11 experienced radiation oncologists. A 63 question survey on GYN-SABR was sent to 11 radiation oncologists (5 countries) who have published original research, conducted trials or have an established program at their institutions. Responses were combined and analyzed at a central institution. Most respondents indicated that salvage therapy (non-irradiated or re-irradiated field) for nodal (81%) and primary recurrent disease (91%) could be considered standard options for SABR in the setting of inability to administer brachytherapy. All other indications should be considered on clinical trials. Most would not offer SABR as a boost in primary treatment off-trial without absolute contraindications to brachytherapy. Multi-modality imaging is often (91%) used for planning including PET, CT contrast and MRI. There is a wide variation for OAR tolerances however small bowel is considered the dose-limiting structure for most experts (91%). Fractionation schedules range from 3 to 6 fractions for nodal/primary definitive and boost SABR. Although SABR has become increasingly standard in other oncology disease sites, there remains a wide variation in both clinical and technical factors when treating GYN cancers. Nodal and recurrent disease is considered a potential indication for SABR whereas other indications should be offered on clinical trials. This study summarizes SABR practices among GYN radiation oncologists while further studies are needed to establish consensus guidelines for GYN-SABR treatment.
Sections du résumé
BACKGROUND
BACKGROUND
Stereotactic Ablative Radiotherapy (SABR) is an effective treatment that improves local control for many tumours. However, the role of SABR in gynecological cancers (GYN) has not been well-established. We hypothesize that there exists considerable variation in GYN-SABR practice and technique. The goal of this study is to describe clinical and technical factors in utilization of GYN-SABR among 11 experienced radiation oncologists.
MATERIALS AND METHODS
METHODS
A 63 question survey on GYN-SABR was sent to 11 radiation oncologists (5 countries) who have published original research, conducted trials or have an established program at their institutions. Responses were combined and analyzed at a central institution.
RESULTS
RESULTS
Most respondents indicated that salvage therapy (non-irradiated or re-irradiated field) for nodal (81%) and primary recurrent disease (91%) could be considered standard options for SABR in the setting of inability to administer brachytherapy. All other indications should be considered on clinical trials. Most would not offer SABR as a boost in primary treatment off-trial without absolute contraindications to brachytherapy. Multi-modality imaging is often (91%) used for planning including PET, CT contrast and MRI. There is a wide variation for OAR tolerances however small bowel is considered the dose-limiting structure for most experts (91%). Fractionation schedules range from 3 to 6 fractions for nodal/primary definitive and boost SABR.
CONCLUSIONS
CONCLUSIONS
Although SABR has become increasingly standard in other oncology disease sites, there remains a wide variation in both clinical and technical factors when treating GYN cancers. Nodal and recurrent disease is considered a potential indication for SABR whereas other indications should be offered on clinical trials. This study summarizes SABR practices among GYN radiation oncologists while further studies are needed to establish consensus guidelines for GYN-SABR treatment.
Identifiants
pubmed: 32000833
doi: 10.1186/s13014-020-1469-8
pii: 10.1186/s13014-020-1469-8
pmc: PMC6993370
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
24Références
Int J Gynecol Cancer. 2010 Oct;20(11 Suppl 2):S64-6
pubmed: 20975365
Pract Radiat Oncol. 2017 Sep - Oct;7(5):295-301
pubmed: 28596092
Front Oncol. 2015 Jun 05;5:126
pubmed: 26097831
Acta Oncol. 2006;45(7):823-30
pubmed: 16982546
Clin Oncol (R Coll Radiol). 2018 Jan;30(1):5-14
pubmed: 29033164
Front Oncol. 2012 Dec 05;2:181
pubmed: 23227452
Clin Oncol (R Coll Radiol). 2017 Jun;29(6):378-384
pubmed: 28209456
J Radiat Oncol. 2017;6(1):31-37
pubmed: 28367276
Int J Radiat Oncol Biol Phys. 2011 Feb 1;79(2):348-55
pubmed: 20472347
Gynecol Oncol. 2017 May;145(2):374-385
pubmed: 28188016
Anticancer Res. 2015 Sep;35(9):5103-10
pubmed: 26254414
Cancer Invest. 2015 May;33(5):180-7
pubmed: 25831242
Front Oncol. 2014 Nov 14;4:279
pubmed: 25452933
Technol Cancer Res Treat. 2010 Oct;9(5):509-14
pubmed: 20815422
Front Oncol. 2016 Nov 22;6:249
pubmed: 27921006
Tumori. 2013 Sep-Oct;99(5):611-6
pubmed: 24362866
Future Oncol. 2014 Nov;10(14):2227-41
pubmed: 25471036
Oncologist. 2020 Feb;25(2):e311-e320
pubmed: 32043791
Gynecol Oncol. 2015 Oct;139(1):40-6
pubmed: 26193429
J Med Imaging Radiat Oncol. 2018 Oct;62(5):692-706
pubmed: 29808571
Lung Cancer. 2013 Nov;82(2):197-203
pubmed: 24051084
Int J Radiat Oncol Biol Phys. 2014 Dec 1;90(5):1083-90
pubmed: 25216857
Radiother Oncol. 2010 Jan;94(1):53-9
pubmed: 20079550
Breast Cancer Res Treat. 2009 Jun;115(3):601-8
pubmed: 18719992
Int J Radiat Oncol Biol Phys. 2016 Jul 15;95(4):1191-200
pubmed: 27130794
Eur J Cancer. 2019 Nov;122:42-52
pubmed: 31614288
Brachytherapy. 2015 Sep-Oct;14(5):587-99
pubmed: 26186975
Clin Genitourin Cancer. 2017 Oct;15(5):e851-e854
pubmed: 28462856
J Neurosurg Spine. 2014 Nov;21(5):711-8
pubmed: 25170656
Lancet. 2019 May 18;393(10185):2051-2058
pubmed: 30982687
Med Phys. 2010 Aug;37(8):4078-101
pubmed: 20879569
Int J Radiat Oncol Biol Phys. 2013 Sep 1;87(1):111-9
pubmed: 23849695
Clin Transl Radiat Oncol. 2018 Jan 11;9:48-60
pubmed: 29594251
Int J Radiat Oncol Biol Phys. 2017 May 1;98(1):196-205.e2
pubmed: 28586960